|Bid||136.50 x 800|
|Ask||136.70 x 1100|
|Day's range||136.20 - 139.00|
|52-week range||79.65 - 142.64|
|Beta (5Y monthly)||1.43|
|PE ratio (TTM)||43.81|
|Earnings date||01 Nov 2021 - 05 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||150.25|
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
SOMERSET, N.J., September 07, 2021--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that members of its executive leadership team will virtually present at the Morgan Stanley 19th Annual Global Healthcare Conference at 1:15 a.m. ET on September 9, 2021.
In this article we are going to estimate the intrinsic value of Catalent, Inc. ( NYSE:CTLT ) by taking the expected...